Bio-Techne Fiscal Q4 Revenues Climb 15 Percent

Aug 07, 2018

|

NEW YORK (GenomeWeb) – Bio-Techne said today that its fiscal 2018 fourth quarter revenues were up 15 percent over Q4 2017. On an organic basis, revenues grew 9 percent year over year.

For the three months ended June 30, the firm reported revenues of $180.3 million compared to $156.6 million in Q4 2017, besting analysts' average estimate of $174.8 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Bio-Techne Fiscal Q4 Revenues Climb 15 Percent

To read the full story....

Breaking News

Hologic Completes $950M Senior Notes Offering

Zymo Research Gets CE-IVD Mark for Sample Collection Devices

Angle Files De Novo FDA Submission for CTC Collection Device in Breast Cancer

LabCorp, Genfit Partner to Commercialize Liver Disease Diagnostic Test

FDA Reissues Emergency Use Authorization for Hologic SARS-CoV-2 Assay for Asymptomatic Testing

Quotient Limited Gets FDA Emergency Use Authorization for Coronavirus Antibody Test

Featured White Papers

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

What's Popular?

FDA Reissues Emergency Use Authorization for Hologic SARS-CoV-2 Assay for Asymptomatic Testing

Cepheid Multiplex SARS-CoV-2, Flu, RSV Test Nabs FDA Emergency Use Authorization

ASU Team Wins $6M in Government Funding to Develop Rapid Saliva Testing System for Coronavirus

Israeli Startup LessTests Uses Single-Step Pooling Software to Multiply COVID-19 Testing Capacity

Abacus Diagnostica Readying Multiplex RT-PCR Test for SARS-CoV-2, Flu, RSV

Sponsorships